Chronic myelogenous leukemia (CML): Resistance to tyrosine kinase inhibitors

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Hochhaus, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTILEUKEMIC AGENT; BCR ABL PROTEIN; CYTARABINE; DASATINIB; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IMATINIB; INTERFERON; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG BINDING SITE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EARLY DIAGNOSIS; GENE IDENTIFICATION; GENE MUTATION; GENETIC CODE; HUMAN; LEUKEMIA RELAPSE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; ONCOGENE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 33749609644     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl273     Document Type: Article

References (40)

1. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-1464.
2. Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004; 91: 1-30.
3. Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321-1331.
4. Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432.
5. Mueller MC, Gattermann N, Lahaye T et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia 2003; 17: 2392-2400.
6. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
7. O'Brien SG, Gullhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
8. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002; 99: 1928-1937.
9. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patents with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002; 99: 3530-3539.
10. Lahaye T, Riehm B, Berger U et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up. Cancer 2005; 103: 1659-1669.
11. Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy. Leukemia 2002; 16: 2190-2196.
12. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to ST1-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
13. Soverini S, Martinelli G, Rosti G et al. ABL mutations in late chronic phase chronic myeloid leukemia patents with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23: 4100-4109.
14. Soverini S, Martinelli G, Amabile M et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem 2004; 50: 1205-1213.
15. Shah NP, Nicoll JM, Nagar B et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (ST1571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125.
16. Hochhaus A. Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol 2003; 40 (Suppl 2): 69-79.
17. Hochhaus A, Kreil S, Corbin A et al. Roots of clinical resistance to ST1-571 cancer therapy. Science 2001; 293: 2163.
18. Schindler T, Bornmann W, Pellicena P et al, Structural mechanism for ST1-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938-1942.
19. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
20. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
21. Cortes J, Giles F, O'Brien S et al. Result of high-dose imatinib mesylate in patents with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 2003; 102: 83-86.
22. Kantarjian HM, Talpaz M, O'Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101: 473-475.
23. Illmer T, Schaich M, Platzbecker U et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401-408.
24. Gambacorti-Passerini C, Zucchetti M, Russo D et al. Apha1 acid glycoprotein binds to imatinib (ST1571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003; 9: 625-632.
25. Muller MC, Lahaye T, Hochhaus A. [Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells]. Dtsch Med Wochenschr 2002; 127: 2205-2207.
26. La Rosée P, Johnson K, Corbin AS et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 2004; 103: 208-215.
27. La Rosée P, Johnson K, O'Dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2002; 30: 729-737.
28. La Rosée P, O'Dwyer ME, Druker BJ. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: A translational perspective. Leukemia 2002; 16: 1213-1219.
29. Berger U, Engelich G, Relter A et al. Imatinib and beyond-to new CML study IV. A randomized controlled comparison of imatinib vs imatinib/ Interferon-alpha vs. imatinib/low-dose AraC vs. imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia. Ann Hematol 2004; 83: 258-264.
30. Sneed TB, Kantarjian HM, Talpaz M et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004; 100: 116-121.
31. Gozzetti A, Tozzuoli D, Crupi R et al. Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI), Eur J Haematol 2003; 71: 313-314.
32. O'Dwyer ME, Mauro MJ, Kurilik G et al. The impact of clonal evolution on response to imatinib mesylate (ST1571) in accelerated phase CML. Blood 2002; 100: 1628-1633.
33. Bumm T, Muller C, Al-Ali HK et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941-1949.
34. Marktel S, Marin D, Foot N, et al. Chronic myeloid leukemia in chronic phase responding to imatinib: The occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica 2003; 88: 260-267.
35. Bacher U, Hochhaus A, Berger U et al. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia 2006; 19: 460-463.
36. O'Dwyer ME, Gatter KM, Loriaux M et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003; 17: 481-487.
37. Shah NP, Tran C, Lee FY et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
38. Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
39. Graham SM, Jorgensen HG, Allan E et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to ST1571 in vitro. Blood 2002; 99: 319-325.
40. La Rosée P, Shen L, Stoffregen EP et al. No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). Hematol J 2003; 4: 413-419.